AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02779647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention consisted of physical activity based on play
Description: The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
Study NCT02607943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
Study NCT02607943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Description: Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
Study NCT03167775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemene Injection/Elemene Oral Emulusion
Study NCT00650845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem®-enhanced MRI
Description: Single IV administration before MRI exam
Study NCT00650845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non-enhanced MRI
Description: non injected MRI
Study NCT03944512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 20 mg Pravastatin taken daily
Study NCT03944512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo pill
Study NCT04340453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with Blood Flow restriction training
Description: 3 times a week for 4 weeks to a total of 12 sessions. BFR cuff (Sports Rehab Tourniquet©) will be used, with a width of 10cm and a length of 116cm or 84cm depending on the diameter of the participants thigh. Therapy sessions will be supervised and in groups. Exercises focus on strengthening the hip extensors and abductors, as well as the quadriceps both in open and closed kinetic chain. Exercises will be carried out using will be set at a load of 30% of 1RM with a limb occlusion pressure (LOP) of 70%. The first set will consist of 30reps. followed by 3 sets of 15reps. at 2:2 (con/ecc) at 60bpm by Metronome app. with auditory cue. Rest between sets will be 30sec and between exercises 2min. Cuffs will be deflated during the resting period between exercises and re-inflated at the beginning of the next exercise. Exercise progression will be individualized based on assessments at the beginning of each week. The duration has been estimated to be approximately 60min. including LOP estimation.
Study NCT04340453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip and Knee Exercise Program
Description: A supervised hip and knee strengthening exercise protocol with a combination of stretching, 3 times a week for 4 weeks to a total of 12 sessions. Exercises focus on hip extensors, abductors, as well as the quadriceps and hamstrings strength. Open Kinetic Chain (OKC) exercises will be executed first followed by CKC exercises. Exercises using weights or mechanical resistance will be set at a load of 70% of 1RM and 3 sets of 10 rep. for each exercise. Elastic band exercises will be set at 10RM for 3 sets. Tempo will be set by the Metronome app installed on a Smartphone at 1:2 (con/ecc) at 60bpm with auditory cue. Rest between sets will be 30sec and between exercises 2min. Exercise progression will be individualized based on assessments at the beginning of each week. The duration of each session is estimated to be approximately 45min, with the exception of the first session of each week which is estimated to be 80min due to the addition of strength testing
Study NCT04340453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching
Description: Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
Study NCT04340453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching
Description: Both groups will receive stretching of the hamstrings, plantar flexors, quadriceps and Iliotibial Band (ITB) in the same manor at the end of each session. Passive stretching will be executed by the physiotherapist with 3x30sec stretch for each muscle group
Study NCT03145259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac Epolamine Patch
Description: patch
Study NCT03145259 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: diclofenac sodium solution
Description: solution
Study NCT03603483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: procedure
Description: Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used
Study NCT04277065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BULLDOG ,A Useful Vascular Occlusion Tourniquet In Laparoscopic Liver Resection
Description: Bulldog is an effectively performed approach for vascular occlusion during laparoscopic hepatectomy than traditional Pringle manuever.
Study NCT04277065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cotton tourniquet
Description: cotton tourniquet
Study NCT01216137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise: Vestibular Rehabilitation
Description: Balance and eye movement training
Study NCT01216137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Bicycle ergometry and stretching
Study NCT00927212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS101 ointment
Description: Twice daily topical application
Study NCT00264537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injections
Description: SC injections
Study NCT00264537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
Study NCT00264537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate capsules
Description: Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
Study NCT00264537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg injections
Description: SC injections
Study NCT00264537 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg injections
Description: SC injections
Study NCT03047421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of accuracy of DES-OSA and P-SAP scores
Description: Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
Study NCT02860104 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: microwave ablation
Description: ultrasound guided percutaneous microwave ablation for breast lesions
Study NCT03094325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre Operative On-pump intraoperative echocardiography
Description: Center tendency parameters(mean, standard deviation) will be reported for each outcome.
Study NCT03094325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre Operative Transesophageal echocardiography (TEE) imaging
Description: Center tendency parameters(mean, standard deviation) will be reported for each outcome.
Study NCT03094325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post Operative On-pump intraoperative echocardiography
Description: Center tendency parameters(mean, standard deviation) will be reported for each outcome.
Study NCT03094325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post Operative Transesophageal echocardiography (TEE) imaging
Description: Center tendency parameters(mean, standard deviation) will be reported for each outcome.
Study NCT00800670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5Ag85A
Description: Single intra-muscular administration of 10\^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
Study NCT00800670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5Ag85A
Description: Single intra-muscular administration of 10\^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
Study NCT01312532 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fixed-bearing (P.F.C.® Sigma)
Description: P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
Study NCT01312532 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: mobile-bearing (P.F.C.® Sigma)
Description: P.F.C.® Sigma, DePuy, Johnson \& Johnson, Leeds, UK
Study NCT06414629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation Based Mentorship Program
Description: In this program, local level mentors were developed to provide regular mentorship on low-dose high-frequency approach in contrast to one-time coaching in a long gap. This program combined the existing package of the continuum of care along with Helping Babies Survive (HBS) \& Helping Mothers Survive (HMS) guidelines, adopting a simulation-based onsite mentoring and coaching approach. The mentors provided monthly mentorship on following seven modules topics to the nurses of the intervention birthing centers:~1. Infection prevention~2. Antenatal care and counseling~3. Essential care of labor and birth~4. Helping babies breathe~5. Bleeding after birth~6. Essential care of labor and birth~7. Postnatal care and counseling~Every monthly session was followed by four weekly practice sessions. The nurses from intervention birthing centers were also called mentees.
Study NCT02651675 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV directed hLDLR gene therapy
Description: AAV directed hLDLR gene therapy is a novel adeno-associated viral (AAV8) vector with human low-density lipoprotein receptor (hLDLR) gene
Study NCT03067077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMILE
Description: SMILE surgery
Study NCT03067077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: LASIK surgery
Study NCT02012140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Study NCT03785015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resume Aspirin within 12 hours
Description: Resume the standard treatment within 12 hours after endoscopic haemostasis
Study NCT03785015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resume Aspirin 72 - 84 hours
Description: Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
Study NCT02706106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee brace
Description: Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
Study NCT02706106 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Knee brace
Description: Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
Study NCT04066426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol
Description: NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
Study NCT01909661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Damira/Celia peptide hydrolyzed casein
Study NCT01909661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Picot riz/Celia rice/Sanutri arroz
Study NCT01442363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-1300 low dose
Description: topical ointment
Study NCT01442363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI-1300 high dose
Description: topical ointment
Study NCT01442363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: topical ointment
Study NCT00538434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT01342081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-111 ophthalmic solution
Study NCT01342081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafluprost ophthalmic solution 0.0015%
Study NCT01342081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
Study NCT02834325 — intervention group
Intervention type: PROCEDURE
Intervention: mechanical ventilation
Study NCT02861157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planet T1D
Description: Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
Study NCT04451070 — intervention group
Intervention type: OTHER
Intervention: Clinic First curriculum
Description: The Clinic First model was designed by the Association of Family Medicine Residency Directors (AFMRD) in collaboration with the University of California San Francisco's (UCSF) Center for Excellence in Primary Care. The components of the Clinic First model are summarized in the Association of American Medical Colleges' (AAMC) publication titled High-Functioning Primary Care Residency Clinics: Building Blocks for Providing Excellent Care and Training. Using the principles of Clinic First, the authors of this study drafted a Family Medicine residency curriculum to be implemented at David Grant Medical Center at the beginning of the 2020-2021 academic year.
Study NCT02618096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02618096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Study NCT00542750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine 1200 mg twice daily for four weeks
Study NCT03941522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early discharge from hospital
Description: Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
Study NCT02492139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pumping CE-marked Symphony Pumpset
Description: Pumping with the CE-marked Symphony Pumpset
Study NCT02492139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pumping BrownieForSymphony Pumpset
Description: Pumping with the the BrownieForSymphony Pumpset
Study NCT02618096 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Membrane sweeping
Study NCT04393987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Compliance Training
Description: Treatment Compliance Training consist of: Introduction of Treatment Compliance Program and Information about the Disease, Therapies for Bipolar Disorder and Importance of Treatment Compliance, Drugs Used for Bipolar Disorder, Effects and Side effects, Strategies to Solve Treatment-Related Problems and Cope with Stress, Beliefs, Attitudes, and Stigmatization Towards Patient/Disease in Bipolar Disorder. The sessions were held in the form of PowerPoint presentations. In the Treatment Compliance Training, lecture, question-answer, homework, sharing experiences, video presentation, summarization were used.The day before each session, patients were phoned and reminded of the time of the session.
Study NCT05326958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRT RCM
Description: Imaging with HRT RCM done only at site 1 (on normal eyes of subjects without DM).
Study NCT05326958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRT RCM-E
Description: imaging done on eyes of all enrolled subjects at site 1 and site 2.
Study NCT00883766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled ovarian hyperstimulation for IVF with a long agonist protocol
Description: Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio \<4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)
Study NCT00883766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation for IVF with an antagonist protocol
Description: Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio \<4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)
Study NCT01644968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 anti-OX40
Description: 0.1 mg/kg anti-OX40 on days 1, 3, and 5
Study NCT01644968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 anti-OX40
Description: .4 mg/kg anti-OX40 on days 1, 3, and 5
Study NCT01644968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 anti-OX40
Description: 2.0 mg/kg anti-OX40 on days 1, 3, and 5
Study NCT01644968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Day 29
Description: Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
Study NCT01644968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Day 1
Description: Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
Study NCT01644968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH Day 1
Description: 1 mg KLH in 1 cc diluent subcutaneously on Day 1.
Study NCT01644968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH Day 29
Description: 1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
Study NCT03661346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case
Study NCT03661346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min
Study NCT00361790 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Description: Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
Study NCT04490772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory tests
Description: Laboratory tests such as CBC, Liver function and CRP
Study NCT04269317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel C
Description: Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
Study NCT00457951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label
Description: ODSH administered open-label
Study NCT00457951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
Description: Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
Study NCT00457951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ODSH
Description: Randomized, Blinded, ODSH Arm